https://www.ncbi.nlm...es/PMC10919985/
UDCA a bile acid, is closely related to the more familiar TUDCA.
Interestingly and oddly the paper doesn't seem too interested in the CRP findings and appears to contradict the data in the discussion.
"Nevertheless, the results of this study revealed that lipid status remained unaffected, along with the inflammatory parameters (IL-6 and CRP)."
Yet there is clear, dramatic improvement in the data of CRP - indeed the paper states:
"Inflammatory parameters did not change significantly. A significant decrease in the intragroup change was found in CRP (1.4 (2.3) vs. 1.9 (2.4); p < 0.05) compared to baseline values in the UDCA group."
IL-6 appears reduced too, but the "deltas" didn't pick it up.
https://www.ncbi.nlm...port=objectonly
Improvements in glucose, HB1AC, waste circumference, blood pressure, cholesterol.
https://www.ncbi.nlm...port=objectonly
https://www.ncbi.nlm...port=objectonly
Markers of superoxide dismutase, catalase, and glutathione all increased in the UDCA group:
https://www.ncbi.nlm...85/figure/fig3/
And so, unsurprisingly, oxidative stress markers improved too:
https://www.ncbi.nlm...85/figure/fig2/
Summary:
"The study demonstrated that an eight-week UDCA administration had beneficial effects on anthropometric status, liver function, and diastolic blood pressure in patients with T2DM. UDCA significantly improved BMI, diastolic blood pressure, liver enzymes (ALT and GGT), and oxidative stress parameters, thus potentially attenuating the progression and complications of diabetes."
NB There is an interview with Professor Steer on longecity where UDCA is discussed. Note too the P3 trials for TUDCA on ALS failed, despite two very promising P2 trials.
https://www.longecit...eases-and-udca/
Edited by ambivalent, 16 July 2024 - 04:34 PM.